March 31, 2011

HELIX BIOPHARMA ANNOUNCES PRIVATE PLACEMENT FOR NET PROCEEDS OF $2.0 MILLION (PDF)

AURORA, Ontario, MARCH 31, 2011 Helix BioPharma Corp. (“Helix” or the “Company”) (TSX, NYSE Amex, FSE:
“HBP”), a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has completed a private placement transaction, issuing 918,365 units for net proceeds of approximately $2.0 million. This transaction follows the private placement announced on March 28, 2011 of 1,652,719 units, and brings the total number of units issued to 2,571,084, for total net proceeds of approximately $5.9 million.